Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Presents Preclinical Data on Primary Hyperoxaluria Type 1 Drug

Premium

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week announced preclinical data showing that its investigational primary hyperoxaluria type 1 (PH1) therapy DCR-PH1 could silence expression of its target by as much as 97 percent in a mouse model of the disease.

PH1 is a rare, inherited autosomal-recessive condition characterized by the liver's inability to metabolize a precursor of oxalate due to disruption of an enzyme called alanine-glyoxylate aminotransferase 1 (AGT1). As a result, calcium oxalate builds up in renal tubules causing kidney stones and fibrosis.

Dicerna's drug is designed to inhibit HAO1, a gene that produces glycolate oxidase, which is an enzyme upstream of AGT1.

In the preclinical studies, which were detailed at the 11th International Primary Hyperoxaluria Workshop, Dicerna and academic collaborators specifically demonstrated that a single dose of DCR-PH1 led to a 97 percent reduction of the HAO1 transcript in the liver and significant reductions in urinary oxalate to near baseline levels.

Dicerna has said it expects to begin Phase I testing of DCR-PH1 in 2015.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.